1-157678811-C-T
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The NM_052939.4(FCRL3):c.2104G>A(p.Asp702Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000564 in 1,613,964 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
NM_052939.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FCRL3 | NM_052939.4 | c.2104G>A | p.Asp702Asn | missense_variant | 15/15 | ENST00000368184.8 | NP_443171.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FCRL3 | ENST00000368184.8 | c.2104G>A | p.Asp702Asn | missense_variant | 15/15 | 1 | NM_052939.4 | ENSP00000357167.3 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152038Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.000103 AC: 26AN: 251254Hom.: 1 AF XY: 0.000140 AC XY: 19AN XY: 135780
GnomAD4 exome AF: 0.0000595 AC: 87AN: 1461808Hom.: 2 Cov.: 33 AF XY: 0.0000756 AC XY: 55AN XY: 727194
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152156Hom.: 0 Cov.: 31 AF XY: 0.0000134 AC XY: 1AN XY: 74408
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 15, 2023 | The c.2104G>A (p.D702N) alteration is located in exon 15 (coding exon 14) of the FCRL3 gene. This alteration results from a G to A substitution at nucleotide position 2104, causing the aspartic acid (D) at amino acid position 702 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at